Modality
ADC
MOA
GLP-1/GIP
Target
HER2
Pathway
RAS/MAPK
ALSUC
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
Oct 2018
→ May 2027
Phase 2Current
NCT08171169
701 pts·ALS
2023-11→2026-10·Active
NCT05971103
23 pts·UC
2018-10→2027-05·Not yet recruiting
724 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-207mo awayPh2 Data· ALS
2027-05-071.1y awayPh2 Data· UC
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2
Not yet…
P2
Active
Catalysts
Ph2 Data
2026-10-20 · 7mo away
ALS
Ph2 Data
2027-05-07 · 1.1y away
UC
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08171169 | Phase 2 | ALS | Active | 701 | HAM-D |
| NCT05971103 | Phase 2 | UC | Not yet recr... | 23 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| BEA-4274 | Beam | Phase 1/2 | ALK | |
| ELV-1411 | Enliven | NDA/BLA | HER2 | |
| PST-2276 | Poseida | Approved | Aβ |